Ronen Arbel
@ArbelRonen
Followers
63
Following
16
Media
0
Statuses
24
Health Outcomes Researcher at @ClalitHealth and @SapirCollege. Focusing on Covid-19, Cardiovascular disease, and their interconnections
Joined July 2011
Proud to be part of this research, and to collaborate with this brilliant team
lnkd.in
This link will take you to a page that’s not on LinkedIn
1
1
4
Amazing comprehensive work by @dan_yamin @ArbelRonen + colleagues on booster safety (1st, 2nd, bivalent). Temporary DECREASE in NON-Covid hospitalizations supports idea that infections exacerbate existing medical probs and boosters briefly prevent this. https://t.co/4T5FKo546A
thelancet.com
This study provides the necessary vaccine safety assurances for at-risk populations to receive timed roll-out booster vaccinations. These assurances could reduce vaccine hesitancy and increase the...
1
7
20
It was my great honor to present our #mpox risk assessment study, which affected the national vaccination study at real time, at the annual public health conference. It was a joint effort at Clalit Health Services, translating the amazing insights of… https://t.co/YfPs97ncOv
linkedin.com
It was my great honor to present our #mpox risk assessment study, which affected the national vaccination study at real time, at the annual public health conference. It was a joint effort at Clalit...
0
0
1
Proud to achieve the 1,000 citations milestone on Google Scholar https://t.co/ZEYznD49r5
linkedin.com
Proud to achieve the 1,000 citations milestone on Google Scholar https://lnkd.in/d_XHT65x
0
0
2
Proud to be part of the editor's choice in the Obesity journal, comparing the #effectiveness and #economics of #weightloss medications. With Prof. Yossi Azuri, Dr. Ariel Hammerman, PhD, Enis Abo Alhasan, and Dr. Benny Slukis.
lnkd.in
This link will take you to a page that’s not on LinkedIn
0
1
1
Proud to be part of this important project .
lnkd.in
This link will take you to a page that’s not on LinkedIn
0
0
1
Proud to share our analysis in the #nejm regarding the need for prioritization of #covidvaccine. The NNT to prevent one #Covid19 death in subjects younger than 65 is over 100,000, costing $12M, prompting the need for prioritizati… https://t.co/yG5rmXT12g
lnkd.in
This link will take you to a page that’s not on LinkedIn
1
1
4
Great example of the magic created when you combine clinical insights and data science
linkedin.com
Great example of the magic created when you combine clinical insights and data science
0
0
2
It was my great honor today to present the impact of Clalit Health Services research on Global #covidvaccine policy in the presidential session of the German Society of Internal Medicine (DGIM)
linkedin.com
It was my great honor today to present the impact of Clalit Health Services research on Global #covidvaccine policy in the presidential session of the German Society of Internal Medicine (DGIM) | 12...
0
0
2
Today, FDA amended the EUAs of the Pfizer-BioNTech and Moderna COVID-19 bivalent mRNA vaccines to simplify the vaccination schedule for most individuals. https://t.co/Cd74KB3n9p What you need to know. 🧵👇
1K
816
1K
Will be presenting in the #lancet late-breaking at the #eccmid2023 on Monday, April 17 at 4:30 PM
0
0
1
Proud to publish our latest manuscript on the latest medications for #weightloss with my colleagues Dr. Ariel Hammerman Dr. Joseph Azuri, Enis Abo Alhasan and Dr. Benni Sluckis, in the esteemed DOM journal https://t.co/nEkNgk5fzx
lnkd.in
This link will take you to a page that’s not on LinkedIn
0
1
4
It was my great pleasure and honor to present the impact of Clalit Health Services research on global policy at the Harvard T.H. Chan School of Public Health Center for Health Decisions Science.
lnkd.in
This link will take you to a page that’s not on LinkedIn
1
0
3
Great honor to be part of this effort, that seems to have contained the #monkeypox epidemic
linkedin.com
Great honor to be part of this effort, that seems to have contained the #monkeypox epidemic
0
0
1
Pfizer’s Paxlovid reduces #COVID19 death by 81% in older adults, but has little effect of people under the age of 64. New study by @ClalitResearch, published in @NEJM, written for @HealthPolicyW. https://t.co/dpiV4cuJ5Z
healthpolicy-watch.news
Pfizer’s COVID-19 oral antiviral Paxlovid was found to reduce the mortality rate among people over the age of 65 by 81% in a new Israeli study published...
2
1
2
During the clinical rollout of nirmatrelvir in Israel in early 2022, most patients (78%) had previous SARS-CoV-2 immunity. Benefit was seen among patients at highest risk for Covid-19 progression, such as those 65+. https://t.co/O6CxzDdIfH
2
31
78
In the latest Clinical Conversations podcast, Joe Elia and @AliRaja_MD sit down with Dr. Ronen Arbel to discuss his study examining #COVID19 #vaccination after infection in Israel. Listen in: https://t.co/IVKYt48w7x
1
3
6
Among patients who had recovered from Covid-19, the receipt of at least one dose of the BNT162b2 vaccine was associated with a significantly lower risk of recurrent infection. https://t.co/AAlsY9sFlv
1
0
2
It was an honor to present our booster study and discuss the tremendous efforts of Clalit Health Services to fight the #omicron surge in Israel in the joint event of the World Health Organization and #ecdc. Thank you Mark Katz for the opportunity to share… https://t.co/3UjIcTJBKg
linkedin.com
It was an honor to present our booster study and discuss the tremendous efforts of Clalit Health Services to fight the #omicron surge in Israel in the joint event of the World Health Organization and...
0
0
1
Proud and grateful for the #nejm acknowledgment of my contribution to the Journal's world-class peer review process
lnkd.in
This link will take you to a page that’s not on LinkedIn
0
0
2